Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 8/20 | 0.41 |
| ▸ | MGLL | Q99685 | 8/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 3/20 | 0.39 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | SI | P14410 | 3/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640188 | 0.81 | MGLL (0.49) | HPGDSMN1; SMN2FAAHMGLLHTT | |
| SCHEMBL5644769 | 0.81 | MGLL (0.49) | HPGDSMN1; SMN2FAAHMGLLHTT | |
| SCHEMBL5641990 | 0.78 | FAAH (0.47) | HPGDSMN1; SMN2FAAHMGLLHTT | |
| SCHEMBL5642585 | 0.76 | FAAH (0.48) | HPGDSMN1; SMN2FAAHMGLLHTT | |
| SCHEMBL5639465 | 0.75 | PKM (0.53) | HPGDSMN1; SMN2FAAHMGLLHTT | |
| SCHEMBL5641596 | 0.75 | FAAH (0.67) | FAAHMGLL | |
| SCHEMBL5642119 | 0.74 | MGLL (0.55) | HPGDSMN1; SMN2FAAHMGLLHTT | |
| SCHEMBL14561698 | 0.74 | FAAH (0.46) | HPGDSMN1; SMN2FAAHMGLLHTT | |
| SCHEMBL5639724 | 0.73 | FAAH (0.45) | HPGDSMN1; SMN2FAAHMGLLHTT | |
| SCHEMBL5642345 | 0.73 | MGLL (0.55) | HPGDSMN1; SMN2FAAHMGLLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208504-B2 | Bicyclic inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| US-7208504-B2 | Bicyclic inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| US-7208504-B2 | Bicyclic inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| EP-1554259-B1 | NOVEL BICYCLIC INHIBITORS OF HORMONE SENSITIVE LIPASE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-12-27 | — | — | EP | disclosed |
| EP-1554259-A1 | NOVEL BICYCLIC INHIBITORS OF HORMONE SENSITIVE LIPASE | Aventis Pharma Deutschland GmbH (DE) | 2005-07-20 | — | — | EP | disclosed |
| US-20040127484-A1 | Novel bicyclic inhibitors of hormone sensitive lipase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| WO-2004035550-A1 | NOVEL BICYCLIC INHIBITORS OF HORMONE SENSITIVE LIPASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127484-A1 | Novel bicyclic inhibitors of hormone sensitive lipase | LIPE, PNLIP, CEL | HPGD 2333/4885SMN1; SMN2 4571/4885FAAH 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.